Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Smallpox: what the dermatologist should know.

Phyllis I Spuls1, Jan D Bos, Donald Rudikoff

  • 1Department of Dermatology, Mount Sinai Medical Center, New York, NY 10029, USA.

Skinmed
|July 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing narrowband and broadband ultraviolet B for atopic dermatitis: new knowledge about an "old" therapy.

The British journal of dermatology·2026
Same author

Drug-Induced Phototoxicity in Vitiligo: The Role of Hydrochlorothiazide in Photosensitivity Dermatitis.

Case reports in dermatological medicine·2025
Same author

Triple-Negative Male Breast Cancer Presenting as Cutaneous Metastasis: A Diagnostic Rarity.

Case reports in oncological medicine·2025
Same author

Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments.

The British journal of dermatology·2025
Same author

Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study.

Acta dermato-venereologica·2025
Same author

Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure.

Trials·2025
Same journal

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Fenofibrate Lipid Lowering Agent.

Skinmed·2025
Same journal

Racial Disparities in the Management of Atopic Dermatitis: An Analysis of the National Ambulatory Medical Care Survey, 2012-2018.

Skinmed·2025
Same journal

"Pseudo-Chik Sign" Following COVID-19: Pigmentation Hitherto Unreported.

Skinmed·2025
Same journal

Hyperpigmented Scaly Lesions in the Axillae.

Skinmed·2025
Same journal

Sweet Syndrome-Like Disorder Induced by the Oxford-AstraZeneca<sup>®</sup> SARS-CoV-2 Vaccine.

Skinmed·2025
Same journal

Lockdown Lessons from Dermatology Consultations during the COVID-19 Pandemic in a Tertiary Care Center.

Skinmed·2025
See all related articles

Smallpox virus remains a bioterrorism threat despite eradication. This review covers smallpox clinical aspects and vaccination reactions, including eczema vaccinatum in atopic dermatitis patients.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Bioterrorism Preparedness

Background:

  • Naturally occurring smallpox was eradicated in 1977.
  • Virus stocks are maintained in US and Russian laboratories.
  • Concerns exist regarding illicit acquisition for bioterrorism.

Purpose of the Study:

  • To review essential clinical aspects of smallpox.
  • To discuss potential reactions to smallpox vaccination.
  • To highlight eczema vaccinatum in atopic dermatitis patients.

Main Methods:

  • Literature review of smallpox clinical manifestations.
  • Review of smallpox vaccination adverse events.
  • Focus on eczema vaccinatum pathogenesis and presentation.

Related Experiment Videos

Main Results:

  • Smallpox remains a potential bioterrorism agent.
  • Vaccination programs are underway for at-risk populations.
  • Eczema vaccinatum is a significant concern for individuals with eczema.

Conclusions:

  • Healthcare providers must be prepared to manage smallpox cases and vaccination reactions.
  • Eczema vaccinatum requires specific clinical recognition and management.
  • Vigilance against smallpox bioterrorism is crucial.